

Supported Self-management Follow-Up for Prostate Cancer Patients

Today's Date:

Patient Name:

DOB:

Hospital Number:

NHS Number:

Dear Dr

After having treatment for prostate cancer at **Trust Name**, **insert patient name** has stable prostate cancer and has now transferred onto our supported self-management follow-up programme.

They have had a consultation which covered the following topics:

- Their diagnosis and prognosis
- The treatment they have had, any ongoing treatment, and possible side effects
- Signs and symptoms to report
- Where to find further help and support – including how to contact the dedicated helpline if they have any concerns

Please find enclosed a copy of their treatment summary which outlines what was discussed with them. Your patient also has a copy of this.

As part of your patient's ongoing care, they will need:

Annual/six monthly PSA tests for a period of 5 years. The patient will be contacted directly with an appointment and results fed back to you and the patient.

At any point during the 3-year follow-up pathway, patients may be contacted to be offered access to any relevant clinical trials that may become available.

At the end of 3 years, **insert patient name** will be discussed in a virtual MDT in order to update any ongoing treatment regimes in light of latest evidence. Any plans from this review will be actioned and a letter will be sent to both you and the patient to provide information regarding any changes and to discharge them from the trust supported self-management pathway.

For any queries, please contact our Prostate Cancer Team on **insert specialist team number**

Signed: Contact Tel no.

Name (*please print*)

GP Name
GP Address

Dear Dr X

Re: Add in patient name, address, date of birth and record number

Your patient has now completed their initial treatment for cancer and a summary of their diagnosis, treatment and on-going management plan are outlined below. The patient has a copy of this summary.

Diagnosis:	Date of Diagnosis:	Organ/Staging Local/Distant
Summary of Treatment and relevant dates:		Treatment Aim:
Possible treatment toxicities and / or late effects:		Advise entry onto primary care palliative or supportive care register Yes / No
		DS 1500 application completed Yes/No Prescription Charge exemption arranged Yes/No
Alert Symptoms that require referral back to specialist team:		Contacts for re referrals or queries: In Hours: Out of hours:
		Other service referrals made: (delete as nec) District Nurse AHP Social Worker Dietician Clinical Nurse Specialist Psychologist Benefits/Advice Service Other
Secondary Care Ongoing Management Plan: (tests, appointments etc.)		
Recommended GP actions in addition to GP Cancer Care Review (e.g. ongoing medication, osteoporosis and cardiac screening)		
Summary of information given to the patient about their cancer and future progress:		
Additional information including issues relating to lifestyle and support needs:		

Completing Doctor:

Signature:

Date:

GP READ CODES FOR COMMON CANCERS (For GP Use only). Other codes available if required. (Note: System codes are case sensitive so always ensure codes are transcribed exactly as below).

System 1	(5 digit codes)	All other systems	Version 3 five byte codes (October 2010 release)
-----------------	------------------------	--------------------------	---

System 1	(5 digit codes)	All other systems	Version 3 five byte codes (October 2010 release)
Diagnosis:		Diagnosis	
Lung Malignant Tumour	XaOKG	Malignant neoplasm of bronchus or lung	B22z.
Carcinoma of Prostate	X78Y6	Malignant neoplasm of prostate	B46..
Malignant tumour of rectum	XE1vW	Malignant neoplasm of Rectum	B141.
Bowel Intestine	X78gK	Malignant neoplasm of Colon	B13..
Large Bowel	X78gN	Malignant neoplasm of female prostate	B34..
Female Malignant Neoplasia	B34..	Malignant neoplasm of male prostate	B35..
Male Malignant Neoplasia	B35..		
Histology/Staging/Grade:		Histology/Staging/Grade:	
Histology Abnormal	4K14.	Histology Abnormal	4K14.
Tumour grade	X7A6m	Tumour staging	4M...
Dukes/Gleason tumour stage	XaOLF	Gleason grading of prostate Ca	4M0..
Recurrent tumour	XaOR3	Recurrence of tumour	4M6..
Local Tumour Spread	X7818		
Mets from 1°	XaFr.	Metastatic NOS	BB13.
Treatment		Treatment	
Palliative Radiotherapy	5149.	Radiotherapy tumour palliation	5149.
Curative Radiotherapy	XalpH	Radiotherapy	7M371
Chemotherapy	x71bL	Chemotherapy	8BAD.
Radiotherapy	Xa851		
Treatment Aim:		Treatment Aim:	
Curative procedure	Xallm	Curative treatment	8BJ0.
Palliative procedure	XaiL3	Palliative treatment	8BJ1.
Treatment toxicities/late effects:			
Osteoporotic #	Xa1TO	At risk of osteoporosis	1409.
Osteoporosis	XaELC	Osteoporosis	N330.
Infection	Xa9ua		
Ongoing Management Plan		Ongoing Management Plan	
Follow up arranged (<1yr)	8H8..	Follow up arranged	8H8..
Follow up arranged (>1yr)	XaL..		
No FU	8HA1.	No follow up arranged	8HA..
Referral PRN	8HAZ.		
Referrals made to other services:		Referrals made to other services:	
District Nurse	XaBsn	Refer to District Nurse	8H72.
Social Worker	XaBsr	Refer to Social Worker	8H75.
Nurse Specialist	XaAgg		
SALT	XaBT6		
Actions required by the GP		Actions required by the GP	
Tumour marker monitoring	Xalqg	Tumour marker monitoring	8A9..
PSA	Xalqh	PSA	43Z2.
Osteoporosis monitoring	XaiSd	Osteoporosis monitoring	66a..
Referral for specialist opinion	Xalst		
Advised to apply for free prescriptions	9D05	Entitled to free prescription	6616.
Cancer Care Review	Xalyc	Cancer Care Review	8BAV.
Palliative Care Review	XaiG1	Palliative Care Plan Review	8CM3.
Medication:		Medication:	
New medication started by specialist	XEOhn	Medication given	8BC2.
Medication changed by specialist	8B316	Medication changed	8B316

System 1	(5 digit codes)	All other systems	Version 3 five byte codes (October 2010 release)
Advice to GP to start medication	XaKbF		
Advice to GP to stop medication	XaJC2		
Information to patient:		Information to patient:	
DS1500 form claim	XaCDx	DS1500 completed	9EB5.
Benefits counselling	6743.	Benefits counselling	6743.
Cancer information offered	XalmL	Cancer information offered	677H.
Cancer diagnosis discussed	XalpL	Cancer diagnosis discussed	8CL0.
Aware of diagnosis	XaQly		
Unaware of prognosis	XaVzE		
Carer aware of diagnosis	XaVzA		
Miscellaneous:		Miscellaneous:	
On GSF palliative care framework	XaJv2	On GSF Palliative Care Framework	8CM1.
GP OOH service notified	Xaltp	GP OOH service notified	9e0..
Carers details	9180.	Carer details	9180.